Anti-Human IL‑23 p19 Reference Antibody (Tildrakizumab, RUO) (HV466026)

Name: Anti-Human IL‑23 p19 Reference Antibody (Tildrakizumab, RUO)
Brand: abinScience
SKU: HV466026
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HV466026
Descripción	Tildrakizumab (HV466026) is a research-grade recombinant antibody targeting SGRF. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG1-kappa
Objetivo	IL-23 subunit alpha, IL-23-A, IL-23p19, IL23A, Interleukin-23 subunit alpha, Interleukin-23 subunit p19, SGRF
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	Q9NPF7
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	MK-3222, SCH900222, 1326244-10-3
Fondo	Interleukin-23 subunit alpha (IL23A) is a ~20 kDa protein. Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity. Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4. This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A. In turn, participates in the early and effective intracellular bacterial clearance. Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells. IL23A is the therapeutic target of guselkumab (Tremfya). 1. Oppmann, B. et al. (2000) Immunity 13, 715-25. PMID: 11114383 2. Bloch, Y. et al. (2018) Immunity 48, 45-58.e6. PMID: 29287995 3. Sun, R. et al. (2020) Cellular and molecular gastroenterology and hepatology 10, 673-697. PMID: 32474165 4. Glassman, CR. et al. (2021) Cell 184, 983-999.e24. PMID: 33606986 5. Parham, C. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 168, 5699-708. PMID: 12023369 6. Wilson, NJ. et al. (2007) Nature immunology 8, 950-7. PMID: 17676044
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Anti-LASV GPC Recombinant Antibody (Fab 37.7) (VK453013)